Betadine 40mg/ml Shampoo

Pays: Irlande

Langue: anglais

Source: HPRA (Health Products Regulatory Authority)

Ingrédients actifs:

Povidone iodinated

Disponible depuis:

Ayrton Saunders Ltd

Code ATC:

D11AC; D11AC06

DCI (Dénomination commune internationale):

Povidone iodinated

Dosage:

40 milligram(s)/millilitre

forme pharmaceutique:

Shampoo

Type d'ordonnance:

Product not subject to medical prescription

Domaine thérapeutique:

Medicated shampoos; povidone-iodine

Statut de autorisation:

Not marketed

Date de l'autorisation:

1975-11-25

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Betadine 40mg/ml Shampoo
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains 40 mg providone iodine
For excipients see Section 6.1.
3 PHARMACEUTICAL FORM
Shampoo
A golden brown, clear, viscous liquid.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
In the management of seborrhoeic conditions or superficial infections.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
1.
Apply to moistened hair and massage into scalp.
2.
Rinse thoroughly.
3.
Treatment should be twice weekly or as directed by the physician.
4.3 CONTRAINDICATIONS
Use in patients with hypsersensitivity to iodine.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Use of the preparation may interfere with tests of thyroid function.
If the condition is aggravated, or there is no improvement, a doctor
should be consulted.
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None stated.
4.6 FERTILITY, PREGNANCY AND LACTATION
Regular use of povidone-iodine should be avoided in pregnant or
lactating women as absorbed iodine can cross the
placental barrier and can be secreted into breast milk.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_2_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_1_
_C_
_R_
_N_
_ _
_2_
_1_
_0_
_6_
_4_
_2_
_7_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
None known.
4.8 UNDESIRABLE EFFECTS
If local irritation or sensitivity develops, discontinue treatment.
4.9 OVERDOSE
In the case of accidental